SEDG) has been a top pick for green-energy investors, with its strong fundamentals and consistent returns. The recent drop in share price has caused concern among shareholders. The company’s long-term performance remains impressive, with a 129% gain over the last five years.\n\nWhile the recent decline may be unsettling, it’s important to look at the bigger picture. SolarEdge’s compound earnings per share (EPS) growth of 4.8% per year over the last five years is slower than the share price growth of 18% per year. \n\nIn addition, there has been significant insider buying in the last three months, which is a positive sign. \n\nWhile the recent sell-off may be concerning, it’s worth noting that even the best stocks can underperform the market in a short period of time. Long-term investors have seen a solid 18% return each year over the last five years, which is a testament to the company’s resilience and growth potential.\n\n The recent drop in share price, SolarEdge Technologies remains a strong and attractive choice for investors seeking growth and resilience in the green-energy industry. Its track record of strong returns and consistent growth make it a company worth considering for long-term investment. \n\nIn a SolarEdge Technologies continues to be a top pick for green-energy investors, with its strong fundamentals and consistent returns.”

'CytoDyn Inc. To Host Investment Community Webcast on December 14, 2023\n\nVANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, has announced that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will be hosting an investment community webcast on Thursday, December 14, 2023.\n\nThe webcast will provide an update on the company's recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the company's next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.\n\nDr. Jacob Lalezari, currently serving as interim CEO, brings over 34 years of industry experience to the company, including nearly 20 years of past experience with leronlimab. He previously served as interim Chief Medical Officer of CytoDyn during 2020, and has been a member of the company’s scientific advisory board for the past several years. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996, and also served as the Chief Medical Officer of Virion Therapeutics in 2018. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for various viral diseases, including clinical trials conducted by the company.\n\nCytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. The company has studied leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.\n\nThis press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements may include statements about leronlimab, its ability to provide positive health outcomes, the company’s ability to resolve the clinical hold imposed by the U.S. Food and Drug Administration (the “FDA”), the company's ability to implement a successful operating strategy for the development of leronlimab, the company's ability to enter into partnerships or collaborations with other companies, the company's expectations regarding the market for leronlimab, and the company's ability to successfully commercialize leronlimab.\n\n CytoDyn Inc. Will be hosting an investment community webcast on December 14, 2023 to provide an update on the company's recent comments from the FDA and its overall development strategy.'